{"filing":{"accession_number":"0001193125-26-251399","cik":"0001676725","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d138848d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"events":[{"id":7800,"run_id":6846,"accession_number":"0001193125-26-251399","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"IDEAYA disclosed complete Phase 2/3 trial data for darovasertib combination in metastatic uveal melanoma, meeting the primary endpoint with statistically significant PFS improvement (6.9 vs 3.1 months, p\u003c0.0001) and favorable secondary endpoints, representing a significant clinical milestone supporting anticipated NDA filing.","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3141,"accession_number":"0001193125-26-251399","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"This is a routine Regulation FD disclosure of an investor presentation at the ASCO Annual Meeting. While the presentation may contain material clinical or business information, the 8-K Item 7.01 filing itself is a procedural disclosure that the presentation was made and is being furnished for transparency. The boilerplate language explicitly disclaims incorporation by reference and Section 18 liability, indicating this is administrative in nature rather than a discrete material event (such as clinical trial results, partnership announcement, or financial guidance).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:44.990819+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3142,"accession_number":"0001193125-26-251399","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"IDEAYA disclosed complete Phase 2/3 trial data for darovasertib combination in metastatic uveal melanoma, meeting the primary endpoint with statistically significant PFS improvement (6.9 vs 3.1 months, p\u003c0.0001) and favorable secondary endpoints. While this is a significant clinical milestone for a registrational trial supporting an anticipated NDA filing, it does not fit neatly into the standard 8-K event taxonomy—it is neither a formal earnings release, M\u0026A activity, restatement, nor other enumerated event type. The disclosure would materially affect investor assessment of the company's pipeline and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:44.990819+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3141,"accession_number":"0001193125-26-251399","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"This is a routine Regulation FD disclosure of an investor presentation at the ASCO Annual Meeting. While the presentation may contain material clinical or business information, the 8-K Item 7.01 filing itself is a procedural disclosure that the presentation was made and is being furnished for transparency. The boilerplate language explicitly disclaims incorporation by reference and Section 18 liability, indicating this is administrative in nature rather than a discrete material event (such as clinical trial results, partnership announcement, or financial guidance).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:44.990819+00:00","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-06-01"},{"id":3142,"accession_number":"0001193125-26-251399","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"IDEAYA disclosed complete Phase 2/3 trial data for darovasertib combination in metastatic uveal melanoma, meeting the primary endpoint with statistically significant PFS improvement (6.9 vs 3.1 months, p\u003c0.0001) and favorable secondary endpoints. While this is a significant clinical milestone for a registrational trial supporting an anticipated NDA filing, it does not fit neatly into the standard 8-K event taxonomy—it is neither a formal earnings release, M\u0026A activity, restatement, nor other enumerated event type. The disclosure would materially affect investor assessment of the company's pipeline and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:44.990819+00:00","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-06-01"}]}